New York, NY (May 17, 2011) - In an effort to estimate the prevalence of chronic kidney disease in adults with type 2 diabetes and examine the care of these individuals, the National Kidney Foundation is launching a multi-site cross-sectional study, Awareness, Detection and Drug Therapy in Type 2 Diabetes Mellitus and Chronic Kidney Disease (ADD-CKD). The study will assess how chronic kidney disease is being identified and managed in type II diabetic patients, in the primary care setting.
Recent research has shown that primary care physicians are extremely busy and have little time to spend discussing risk factors and preventative steps with patients at risk for kidney disease. One study found that only half of primary care doctors discussed chronic kidney disease, with their diabetic patients. And when it was discussed, half of doctors spoke about CKD for 33 seconds or less – an average of only 3% of the total visit time.
"Primary care physicians are our first line of defense against one of the world's top killers," said Lynda Szczech, MD, MSCE, President of the National Kidney Foundation. "More than 26 million Americans already have chronic kidney disease, and millions more are at risk and don't even know it. Early detection and treatment of kidney disease in patients can help slow progression and reduce cardiovascular events and delay time to kidney failure. The goal of this study is to increase the awareness and management of chronic kidney disease in diabetic patients.”
The ADD-CKD study will recruit 460 primary care practitioner providers. Each provider will recruit 21 type 2 diabetes patients, for a total of 9,660 patients. The study, to be administered by primary care physicians and primary care nurse practitioners will use a primary care provider survey, a patient physical exam and medical history, lab testing, including blood and urine and patient quality of life questionnaires. Enrollment begins in June 2011. Primary care providers can fill out an online feasibility survey at http://www.kidney.org/professionals/pdf/5-11-2011-Amended-Feasibility-SURVEY.pdf
The National Kidney Foundation is dedicated to preventing and treating kidney and urinary tract diseases, improving the health and well being of individuals and families affected by these diseases and increasing availability of all organs for transplantation. For more information on ADD-CKD contact Rebecca Stewart at Rebeccas@kidney.org
The ADD-CKD study is sponsored by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly & Company